Next Article in Journal
Systematic Identification and Expression Analysis of the Auxin Response Factor (ARF) Gene Family in Ginkgo biloba L.
Previous Article in Journal
Thyroid Homeostasis: An Intricate Network of Production, Transport, Metabolism and Receptors Interaction
 
 
Article

Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines—An Isobolographic Analysis

1
Department of Pathophysiology, Medical University of Lublin, 20-090 Lublin, Poland
2
Department of Medical Anthropology, Institute of Rural Health, 20-950 Lublin, Poland
*
Author to whom correspondence should be addressed.
Academic Editor: Alfonso Baldi
Int. J. Mol. Sci. 2022, 23(12), 6752; https://doi.org/10.3390/ijms23126752
Received: 3 May 2022 / Revised: 11 June 2022 / Accepted: 15 June 2022 / Published: 17 June 2022
(This article belongs to the Section Molecular Oncology)
The medical application of cannabidiol (CBD) has been gathering increasing attention in recent years. This non-psychotropic cannabis-derived compound possesses antiepileptic, antipsychotic, anti-inflammatory and anxiolytic properties. Recent studies report that it also exerts antineoplastic effects in multiple types of cancers, including melanoma. In this in vitro study we tried to reveal the anticancer properties of CBD in malignant melanoma cell lines (SK-MEL 28, A375, FM55P and FM55M2) administered alone, as well as in combination with mitoxantrone (MTX) or cisplatin (CDDP). The effects of CBD on the viability of melanoma cells were measured by the MTT assay; cytotoxicity was determined in the LDH test and proliferation in the BrdU test. Moreover, the safety of CBD was tested in human keratinocytes (HaCaT) in LDH and MTT tests. Results indicate that CBD reduces the viability and proliferation of melanoma-malignant cells and exerts additive interactions with MTX. Unfortunately, CBD produced antagonistic interaction when combined with CDDP. CBD does not cause significant cytotoxicity in HaCaT cell line. In conclusion, CBD may be considered as a part of melanoma multi-drug therapy when combined with MTX. A special attention should be paid to the combination of CBD with CDDP due to the antagonistic interaction observed in the studied malignant melanoma cell lines. View Full-Text
Keywords: cannabinoids; cannabidiol; melanoma; in vitro study; drug interactions cannabinoids; cannabidiol; melanoma; in vitro study; drug interactions
Show Figures

Figure 1

MDPI and ACS Style

Marzęda, P.; Wróblewska-Łuczka, P.; Drozd, M.; Florek-Łuszczki, M.; Załuska-Ogryzek, K.; Łuszczki, J.J. Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines—An Isobolographic Analysis. Int. J. Mol. Sci. 2022, 23, 6752. https://doi.org/10.3390/ijms23126752

AMA Style

Marzęda P, Wróblewska-Łuczka P, Drozd M, Florek-Łuszczki M, Załuska-Ogryzek K, Łuszczki JJ. Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines—An Isobolographic Analysis. International Journal of Molecular Sciences. 2022; 23(12):6752. https://doi.org/10.3390/ijms23126752

Chicago/Turabian Style

Marzęda, Paweł, Paula Wróblewska-Łuczka, Małgorzata Drozd, Magdalena Florek-Łuszczki, Katarzyna Załuska-Ogryzek, and Jarogniew J. Łuszczki. 2022. "Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines—An Isobolographic Analysis" International Journal of Molecular Sciences 23, no. 12: 6752. https://doi.org/10.3390/ijms23126752

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop